Literature DB >> 33062700

Identification of Circular RNA-MicroRNA-Messenger RNA Regulatory Network in Atrial Fibrillation by Integrated Analysis.

Tao Liu1, Guoru Zhang1, Yaling Wang1, Mingyue Rao1, Yang Zhang1, Anjun Guo1, Mei Wang1.   

Abstract

BACKGROUND: Circular RNA (circRNA) is a noncoding RNA that forms a closed-loop structure, and its abnormal expression may cause disease. We aimed to find potential network for circRNA-related competitive endogenous RNA (ceRNA) in atrial fibrillation (AF).
METHODS: The circRNA, miRNA, and mRNA expression profiles in the heart tissue from AF patients were retrieved from the Gene Expression Omnibus database and analyzed comprehensively. Differentially expressed circRNAs (DEcircRNAs), differentially expressed miRNAs (DEmiRNAs), and differentially expressed mRNAs (DEmRNAs) were identified, followed by the establishment of DEcircRNA-DEmiRNA-DEmRNA regulatory network. Functional annotation analysis of host gene of DEcircRNAs and DEmRNAs in ceRNA regulatory network was performed. In vitro experiment and electronic validation were used to validate the expression of DEcircRNAs, DEmiRNAs, and DEmRNAs.
RESULTS: A total of 1611 DEcircRNAs, 51 DEmiRNAs, and 1250 DEmRNAs were identified in AF. The DEcircRNA-DEmiRNA-DEmRNA network contained 62 circRNAs, 14 miRNAs, and 728 mRNAs. Among which, two ceRNA regulatory pairs of hsa-circRNA-100053-hsa-miR-455-5p-TRPV1 and hsa-circRNA-005843-hsa-miR-188-5p-SPON1 were identified. In addition, six miRNA-mRNA regulatory pairs including hsa-miR-34c-5p-INMT, hsa-miR-1253-DDIT4L, hsa-miR-508-5p-SMOC2, hsa-miR-943-ACTA1, hsa-miR-338-3p-WIPI1, and hsa-miR-199a-3p-RAP1GAP2 were also obtained. MTOR was a significantly enriched signaling pathway of host gene of DEcircRNAs. In addition, arrhythmogenic right ventricular cardiomyopathy, dilated cardiomyopathy, and hypertrophic cardiomyopathy were remarkably enriched signaling pathways of DEmRNAs in DEcircRNA-DEmiRNA-DEmRNA regulatory network. The expression validation of hsa-circRNA-402565, hsa-miR-34c-5p, hsa-miR-188-5p, SPON1, DDIT4L, SMOC2, and WIPI1 was consistent with the integrated analysis.
CONCLUSION: We speculated that hsa-circRNA-100053-hsa-miR-455-5p-TRPV1 and hsa-circRNA-005843-hsa-miR-188-5p-SPON1 interaction pairs may be involved in AF.
Copyright © 2020 Tao Liu et al.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33062700      PMCID: PMC7545447          DOI: 10.1155/2020/8037273

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


1. Introduction

Atrial fibrillation (AF) is one of the most common arrhythmias and associated with heart failure [1-4]. Age, gender, obesity, and heart valve abnormalities are important factors of AF [4-6]. AF can also lead to heart failure hospitalization and death [7]. However, current treatment of AF may have adverse reactions [8, 9]. The pathogenesis of AF remains unclear. Further study of the underlying mechanisms of AF may provide new treatments for AF [10]. Circular RNAs (circRNAs) (with a covalent closed-loop structure) are considered to be the key to pathogenesis of heart disease, providing a new perspective for the pathogenesis of AF [11]. circRNA plays a crucial role in several pathophysiological processes [4, 12]. In heart disease, circRNAs function as the regulator of miRNA levels. circRNAs may be the potential biomarker. Moreover, bioinformatics analysis provides a novel perspective on circRNAs involved in AF and establishes the foundation for future research of the potential roles of circRNAs in AF [13]. miRNAs play a variety of roles in atrial fibrillation, including regulation of electrical remodeling and modulation of structural remodeling of cardiac tissue. Different miRNAs were confirmed to be up- or downregulated in AF patients [14]. Jiang et al. found the regulatory networks of has_circRNA_100612-has-miR-133b-KCNIP1/JPH2/ADRB1 and has_circRNA_405917/hsa_circRNA_008132/hsa_circRNA_104052/hsa_circRNA_101021/hsa_circRNA_101020/hsa_circRNA_102341-has-miR-892b-GJA1 in the heart tissue of AF patients [4]. However, the potential mechanism of AF remains to be studied. In this study, we performed integrated analysis based on GEO datasets to further identify dysregulated circRNAs in AF.

2. Methods

2.1. Data Collection

We obtained the expression profiles of circRNA, miRNA, and mRNA from GEO datasets by searching keywords (“Atrial fibrillation” [All Fields]) AND (“Homo sapiens” [porgn] AND “gse” [Filter]). We selected data according to the following criteria: (1) the selected dataset must be genome-wide circRNA/miRNA/mRNA transcriptome data; (2) these data were obtained from the heart tissues of the patients in the AF group and the normal control (NC) group (without drug stimulation or transfection); (3) standardized or original datasets were considered in this study. One circRNA expression dataset (GSE129409), two miRNA expression datasets (GSE68475 and GSE70887), and one mRNA expression dataset (GSE31821) were selected (Supplementary Table 1).

2.2. Identification of Differentially Expressed circRNAs, miRNAs, and mRNAs

Firstly, the probes corresponding to multiple circRNAs/miRNAs/mRNAs were removed. Only the single probe with the largest average expression was retained in multiple probes corresponding to circRNAs/miRNAs/mRNAs. After this treatment, qualified circRNAs/miRNAs/mRNAs were used for further analysis. Then, LIMMA package analysis was used to identify differentially expressed circRNAs and mRNAs. The metaMA package analysis was used to identify differentially expressed miRNAs. P value < 0.05 was the screening criteria for differentially expressed circRNAs, miRNAs, and mRNAs. Detailed data analysis process was performed as previously described [15].

2.3. Functional Annotation

To assess the functional annotations of host gene of DEcircRNAs and DEmRNAs in ceRNA regulatory network, Gene Ontology (GO) classification and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were conducted based on the online software GeneCodis3. Statistical significance was with the cutoff criteria of P value < 0.05.

2.4. Construction of ceRNA (DEcircRNA-DEmiRNA-DEmRNA) Regulatory Network

Firstly, starBase v3.0 was used to establish DEcircRNA-DEmiRNA regulatory network. Then, miRWalk 3.0 (http://mirwalk.umm.uni-heidelberg.de/) was utilized to find the target differentially expressed mRNAs of differentially expressed miRNAs. Finally, the DEcircRNA-DEmiRNA regulatory network was fused with the DEmiRNA-DEmRNA regulatory network to further construct the ceRNA (DEcircRNA-DEmiRNA-DEmRNA) regulatory through Cytoscape (version 3.6.1) software.

2.5. In Vitro Validation

The blood samples from 10 patients with AF and 10 healthy individuals were obtained for quantitative real-time polymerase chain reaction (qRT-PCR) validation. The inclusion criteria of AF patients were as follows: (1) patients were diagnosed according to the 2014 American Heart Association (AHA)/American College of Cardiology (ACC)/American Heart Rhythm Society (HRS) AF guidelines and confirmed by electrocardiogram (ECG) or Holter monitor, (2) the onset of AF in the patients was at least once a month, (3) patients were under the age of 85, (4) patients with normal liver and kidney function, and (5) patients visited the doctor at least 2 times and took medicine regularly. The exclusion criteria of AF patients were as follows: (1) patients with AF with hemodynamic disorders or malignant arrhythmia; (2) patients were 85 years old and above; (3) patients with AF with chronic cardiac insufficiency (grades II-IV); (4) patients with other severe systemic diseases, or liver and kidney failure; and (5) patients with ischemic heart disease, valvular disease, cardiomyopathy, rheumatic heart disease, primary pulmonary hypertension, and connective tissue disease. There were no statistically significant differences in age, sex, and body mass index (BMI) between AF patients and the normal individuals. We obtained the written informed consent and the approval from the ethics committee of the Second Hospital of Hebei Medical University. Total RNA was isolated with the TRIzol reagent following the manufacturer's protocol. Based on SuperReal PreMix Plus in ABI 7500 Real-Time PCR Detection System, the qRT-PCR reactions were performed. In the 2- method, relative circRNA/miRNA/mRNA expression was determined. Human ACTB and GAPDH were used as endogenous controls for mRNA. In addition, human GAPDH and U6 were used as endogenous controls for circRNA and miRNA expression, respectively.

2.6. Electronic Validation

The GSE135445 dataset (involving 15 AF patients and 15 normal controls) was used to validate the expression of identified differentially expressed mRNAs. The result was presented as box plots. Statistical significance was ascribed to P value < 0.05.

3. Results

3.1. Differentially Expressed circRNAs, miRNAs, and mRNAs

Compared to normal heart tissues, a total of 1250 DEmRNAs (636 upregulated and 614 downregulated mRNAs) and 51 DEmiRNAs (14 upregulated and 38 downregulated miRNAs) were identified in AF (Figures 1(a) and 1(b)). Among them, RAP1GAP2 and ACTA1 were the most upregulated and downregulated mRNAs, respectively (Table 1); hsa-miR-508-5p and hsa-miR-99a were the most upregulated and downregulated miRNAs, respectively (Table 2). A total of 1611 DEcircRNAs (592 upregulated and 1019 downregulated circRNAs) were obtained in AF (Figure 1(c)). Among them, hsa_circRNA_405811 and hsa_circRNA_103752 were the most upregulated and downregulated circRNAs, respectively (Table 3).
Figure 1

The heat map of top 100 upregulated and downregulated differentially expressed mRNAs (a), all differentially expressed miRNAs (b), and differentially expressed circRNAs (c) in AF.

Table 1

Top 10 upregulated and downregulated mRNAs in AF.

SymbolLog FC P valueUp/down
RAP1GAP20.5645835.81E − 05Up
LOC3885880.7354150.000103Up
DDIT4L0.7242980.000187Up
PCDHB50.2823180.00063Up
TRPV10.3320220.000843Up
LOC1005098860.6036180.000911Up
C1orf930.3703580.000979Up
CCDC300.2798240.001004Up
CCL180.5792820.001226Up
MPHOSPH90.2952360.001321Up
ACTA1-1.409168.30E − 06Down
COLEC11-0.684642.85E − 05Down
SMOC2-0.507368.63E − 05Down
ITGB1BP3-0.481150.000102Down
INMT-0.433380.00019Down
WIPI1-0.431740.000304Down
B3GNT2-0.64470.000379Down
OSTF1-0.328140.000585Down
HEY1-0.504530.0006Down
SPON1-0.586980.000735Down

FC: fold change.

Table 2

Upregulated and downregulated miRNAs in AF.

IDCombined ES P valueUp/down
hsa-miR-99a-1.9483257441.58E − 05Down
hsa-miR-199a-5p-1.4778541970.000457589Down
hsa-miR-508-5p1.4184884870.00088982Up
hsa-miR-199a-3p-1.3201424840.00135394Down
hsa-miR-365-1.2802029410.002621664Down
hsa-miR-3721.2045140160.003633868Up
hsa-miR-26a-1-1.1404858140.004661322Down
hsa-miR-6221.1198500330.005370597Up
hsa-miR-1321.0728033960.007384577Up
hsa-miR-302d-1.0479589640.008664093Down
hsa-let-7f-1.0335485050.009485724Down
hsa-miR-11811.0067115720.011230985Up
hsa-miR-323-3p-0.993276060.012491569Down
hsa-miR-514-0.9822606440.013357392Down
hsa-miR-943-0.970259730.014154981Down
hsa-miR-328-1.0275393950.014920866Down
hsa-miR-371-5p0.963451640.016747391Up
hsa-let-7i-0.9285575630.019493344Down
hsa-miR-34c-5p0.9184819630.019551512Up
hsa-miR-2980.9144351470.020064925Up
hsa-miR-1224-5p0.9214773540.020188607Up
hsa-miR-1253-0.9101714710.020573062Down
hsa-let-7g-0.9147086250.020978097Down
hsa-miR-660-0.924396330.021108962Down
hsa-miR-455-5p-1.0650946460.021971426Down
hsa-miR-105-0.8738851940.025653065Down
hsa-miR-7-2-0.8709388420.026112318Down
hsa-miR-342-3p-0.9140171070.029399291Down
hsa-miR-412-0.8484829910.029880717Down
hsa-miR-3450.8476347020.030183762Up
hsa-miR-188-5p0.847740530.03099467Up
hsa-miR-532-5p-0.8474453910.032511465Down
hsa-miR-1296-0.831888830.033097822Down
hsa-miR-150-0.923573570.034421637Down
hsa-miR-551b-0.8215432890.035474621Down
hsa-miR-181a-2-0.8165585010.036074016Down
hsa-miR-338-3p-0.8228008910.03637736Down
hsa-miR-654-3p-0.8107949890.037860622Down
hsa-miR-4980.8068711690.038377453Up
hsa-miR-944-0.8013112360.039480709Down
hsa-miR-208b0.798393230.040113362Up
hsa-miR-16-2-0.8249297730.040444012Down
hsa-miR-143-0.7913854740.042083126Down
hsa-miR-597-0.7899678140.04214698Down
hsa-miR-433-0.7880376980.042547929Down
hsa-miR-24-2-0.7828121240.043926008Down
hsa-miR-450a-0.7819787460.044964884Down
hsa-miR-802-0.7765473060.045503217Down
hsa-miR-1200-0.768254280.047587947Down
hsa-miR-513c0.7672048680.04833756Up
hsa-miR-891a-0.7608130390.049622889Down

ES: effect size. The bigger the absolute value of combined ES, the bigger the fold change.

Table 3

Top 10 upregulated and downregulated circRNAs in AF.

IDAliasLog FC P valueUp/down
hsa_circRNA_4058111.9109085.86E − 05Up
hsa_circRNA_058161hsa_circ_00581611.6259180.000148Up
hsa_circRNA_100693hsa_circ_00201741.4725560.00026Up
hsa_circRNA_4048141.4856930.000344Up
hsa_circRNA_102950hsa_circ_00587941.5754020.000409Up
hsa_circRNA_102949hsa_circ_00587921.482370.000424Up
hsa_circRNA_001873hsa_circ_00018731.3947860.000522Up
hsa_circRNA_100372hsa_circ_00150041.3500130.000533Up
hsa_circRNA_4025651.2996060.000622Up
hsa_circRNA_4067521.3946820.00064Up
hsa_circRNA_103752hsa_circ_0006867-1.273760.000302Down
hsa_circRNA_102831hsa_circ_0001074-1.413860.000534Down
hsa_circRNA_104315hsa_circ_0079480-1.492410.000718Down
hsa_circRNA_079477hsa_circ_0079477-1.286230.000724Down
hsa_circRNA_005791hsa_circ_0005791-1.79860.001027Down
hsa_circRNA_103416hsa_circ_0005299-1.874060.001123Down
hsa_circRNA_104750hsa_circ_0008678-1.076040.001253Down
hsa_circRNA_004825hsa_circ_0004825-1.082050.001293Down
hsa_circRNA_004491hsa_circ_0004491-1.170350.001311Down
hsa_circRNA_406303-1.300320.001433Down

FC: fold change.

3.2. Functional Enrichment Analysis

A total of 342 host genes of DEcircRNAs were obtained. GO analysis indicated that these host genes were significantly enriched in biological processes of protein modification process (P = 1.99E − 09), RNA metabolic process (P = 2.57E − 08), and chromatin modification (P = 3.21E − 08) (Figure 2(a)). According to the KEGG pathway enrichment analysis, several pathways were identified, including ubiquitin-mediated proteolysis (P = 6.27E − 09), the mTOR signaling pathway (P = 0.000127701), and the MAPK signaling pathway (P = 0.000203168) (Figure 2(b)). In addition, significantly enriched cytological components and molecular functions of host genes are shown in Supplementary Figure 1.
Figure 2

Significantly enriched biological processes and KEGG pathways of host genes of differentially expressed circRNAs. (a) BP: biological process. (b) KEGG pathways. The x-axis shows counts of host genes enriched in biological processes or KEGG pathways, and the y-axis shows biological processes or KEGG pathways.

3.3. ceRNA (DEcircRNA-DEmiRNA-DEmRNA) Regulatory Network

We predicted 94 DEmiRNA-DEcircRNA interactions by starBase v3.0 with a strict mode. The network was constructed by Cytoscape 3.6.1, which included 79 nodes and 94 edges (Figure 3). We also collected 32932 experimentally validated DEmiRNA-DEmRNA interactions from miRWalk 3.0 and established network by Cytoscape 3.6.1, which included 785 nodes and 2099 edges (Supplementary Figure 2). The ceRNA network contained 62 circRNAs, 14 miRNAs, and 728 mRNAs (Supplementary Figure 3). Among which, two ceRNA regulatory pairs of hsa-circRNA-100053-hsa-miR-455-5p-TRPV1 and hsa-circRNA-005843-hsa-miR-188-5p-SPON1 were identified. In addition, GO enrichment analysis revealed that these DEmRNAs were significantly enriched in biological processes of signal transduction (P = 7.69E − 14), multicellular organismal development (P = 3.49E − 09), and regulation of transcription from RNA polymerase II promoter (P = 1.12E − 07) (Figure 4(a)). According to the KEGG pathway enrichment analysis, several pathways were significantly enriched, such as arrhythmogenic right ventricular cardiomyopathy (P = 2.28E − 05), dilated cardiomyopathy (P = 0.000590151), and hypertrophic cardiomyopathy (P = 0.00173912) (Figure 4(b)). In addition, significantly enriched cytological components and molecular functions of these DEmRNAs are shown in Supplementary Figure 2.
Figure 3

The cirRNA-miRNA network in AF. Rectangle and triangle represent circRNAs and miRNAs, respectively.

Figure 4

Significantly enriched biological processes and KEGG pathways of differentially expressed mRNAs in ceRNA regulatory network. (a) BP: biological process. (b) KEGG pathways. The x-axis shows counts of host genes enriched in biological processes or KEGG pathways, and the y-axis shows biological processes or KEGG pathways.

3.4. qRT-PCR Validation of Selected DEmRNAs, DEmiRNAs, and DEcircRNAs

In this study, 10 patients with AF and 10 normal individuals were enrolled. Clinical information of these patients is shown in Supplementary Table 2. Two DEmRNAs (including SPON1 and DDIT4L), two DEmiRNAs (including hsa-miR-34c-5p and hsa-miR-188-5p), and one DEcircRNAs hsa-circRNA-402565 were selected randomly for qRT-PCR validation (Figure 5). DDIT4L, hsa-miR-34c-5p, hsa-miR-188-5p, and hsa-circRNA-402565 were upregulated, while SPON1 was downregulated in AF. The qRT-PCR results were in line with our integrated analysis.
Figure 5

The qRT-PCR results of the DEmRNAs, DEmiRNAs, and DEcircRNAs in AF. The x-axis and the y-axis represent the group and relative expression of DEmRNAs/DEmiRNAs/DEcircRNAs, respectively. ∗P < 0.05 and ∗∗P < 0.01.

3.5. Electronic Validation of Selected mRNAs

In this study, two differentially expressed mRNAs (SMOC2 and WIPI1) and three host genes of circRNAs (MFN2, ZNF880, and LRBA) were randomly selected for validation (Figure 6). The result showed that SMOC2 and WIPI1 were downregulated in AF, which was consisted with our integrated analysis. The expression of MFN2, ZNF880, and LRBA was upregulated in AF. However, MFN2, ZNF880, and LRBA were not differentially expressed mRNAs in this study. Further study of MFN2, ZNF880, and LRBA in AF is needed.
Figure 6

The box plots of SMOC2, WIPI1, MFN2, ZNF880, and LRBA in AF. The x-axis and the y-axis represent the group and expression of mRNAs, respectively.

4. Discussion

Mitofusin 2 (MFN2) is the host gene of hsa_circRNA_100053. MFN2 plays a key role in normal cardiac development [16]. MFN2 could regulate heart failure-related mitophagy by altering the mitochondrial membrane potential [17]. Chen et al. found that deletion of MFN2 leads to a spontaneous lethal dilated cardiomyopathy in mice [18]. In this study, we found that hsa_circRNA_100053 was downregulated in the heart tissue of AF patients. Moreover, downregulated hsa-miR-455-5p and target upregulated transient receptor potential vanilloid 1 (TRPV1) were under the regulation of hsa_circRNA_100053. Huang et al. reported that hsa-miR-455-5p was related to hypoxia-induced cardiomyocytes injury [19]. TRPV1 is a nonselective ion channel that preferentially obtains calcium from painful stimuli. In addition to traditional pain activation of TRPV1, TRPV1 can also be used as a universal sensor for cell damage including hypoxia. Direct activation of TRPV1 has been shown to produce cardioprotective effects on ischemia and reperfusion injury [20]. In addition, blocking TRPV1 limits the long-term preconditioning-induced cardioprotection of laparotomy [20]. An experimental study showed that TRPV1 inhibition blocked ischemic preconditioning- (IPC-) induced myocardial protection [21]. These reports suggested that hsa_circRNA_100053, hsa-miR-455-5p, and TRPV1 may play an important role in heart protection. Our study indicated that the interaction of hsa_circRNA_100053-hsa-miR-455-5p-TRPV1 may be involved in the process of AF. Recently, there was no report about the association between hsa_circRNA_005843 and AF. Interestingly, we found that hsa_circRNA_005843 was downregulated in the heart tissue of patients with AF. Furthermore, upregulated hsa-miR-188-5p and target downregulated spondin 1 (SPON1) were regulated by hsa_circRNA_005843. hsa-miR-188-5p plays an important regulation role in the renin-angiotensin system [22]. It has been demonstrated that hsa-miR-188-5p is involved in murine cardiomyocyte biogenesis [23]. Decreased expression of hsa-miR-188-5p is found in hyperhomocysteinemia cardiomyocytes [24]. SPON1, a member of antiangiogenic family, is a sensitive plasma biomarker for early myocardial injury [25]. This indicated that hsa-miR-188-5p and SPON1 play roles in angiogenesis, which is associated with cardiomyocyte biogenesis. Our result suggested that the interaction between hsa_circRNA_005843, hsa-miR-188-5p, and SPON1 could be associated with AF. We also found several DEmiRNA (upregulation)-DEmRNA (downregulation) regulatory pairs such as hsa-miR-34c-5p-indolethylamine N-methyltransferase (INMT), hsa-miR-1253-DNA damage-inducible transcript 4 like (DDIT4L), hsa-miR-508-5p-SPARC-related modular calcium binding 2 (SMOC2), hsa-miR-943-actin alpha 1, skeletal muscle (ACTA1), hsa-miR-338-3p-WD repeat domain, phosphoinositide-interacting 1 (WIPI1), and DEmiRNA (downregulation)-DEmRNA (upregulation) regulatory pair including hsa-miR-199a-3p-RAP1 GTPase-activating protein 2 (RAP1GAP2). Greco et al. found increased expression of hsa-miR-34c in the failing myocardium of diabetic patients [26]. INMT is differentially expressed in myocardial infarction [27]. No association between hsa-miR-1253 and AF has been reported. DDIT4L is expressed in cardiomyocytes and myocardial tissues of pathologically stressed mice, cultured neonatal rat ventricular myocyte (NRVM) models and patients with dilated cardiomyopathy. It is worth noting that pathological stress did not alter the abundance of the relevant DDIT4. DDIT4L, localizes to early endosomes, is a key regulator of NRVMs that inhibits stress-induced autophagy via mTORC1 [28]. Studies by Simonson et al. showed that cardiac pathological stress activates DDIT4L and induces autophagy by inhibiting the mTORC1 signaling pathway [28]. hsa-miR-508-5p is a potential diagnostic and prognostic marker for heart failure patients [29]. SMOC2 is involved in the inflammatory damage in the heart [30]. hsa-miR-943 is remarkably upregulated in acute ischemic stroke patients [31]. ACTA1, a contractile fiber gene, is associated with heart failure and cardiac hypertrophy [32, 33]. hsa-miR-338-3p is involved in heart failure and acute myocardial infarction [34, 35]. WIPI1 regulates mitochondrial oxidative signaling in cardiac myocytes [36]. hsa-miR-199a-3p is related to the pathophysiology of heart failure [37]. The expression of hsa-miR-199a-3p was downregulated in myocardial infarction [38]. RAP1GAP2 is associated with Chagas cardiomyopathy [39]. Thus, it can be seen that these miRNAs and target mRNAs play a key role in various cardiac pathologic processes, such as myocardial infarction, dilated cardiomyopathy, cardiac pathological stress, cardiac hypertrophy, and inflammatory damage. It is suggested that above DEmiRNAs and target DEmRNAs may be involved in the process of AF. In addition, we found that hsa-circRNA-402565 was upregulated in the heart tissue of AF patients. Interestingly, qRT-PCR validated the expression of hsa-circRNA-402565. hsa-circRNA-402565 is downregulated in patients with ventricular septal defect [40]. It is noted that hsa-circRNA-405811 and hsa-circRNA-103752 were, respectively, the most upregulated and downregulated circRNAs in AF. hsa-miR-99a was the most downregulated miRNA in AF. Zinc finger protein 880 (ZNF880) is the host gene of hsa-circRNA-405811. The inactivating mutation of ZNF880 is found in isolated cardiac myxoma tissue samples [41]. LPS responsive beige-like anchor (LRBA) protein is the host gene of hsa-circRNA-103752. It is reported that LRBA is involved in signal transduction and vesicle trafficking in cardiogenesis [42]. The expression of LRBA is decreased 2 d after myocardial infarction [43]. It is suggested that hsa-miR-99a is involved in cardioprotective in postinfarction left ventricular remodelling [44]. Thus, it can be seen that these circRNAs involve in cardiogenesis and cardioprotection. Our result indicated that hsa-circRNA-402565, hsa-circRNA-405811, hsa-circRNA-103752, and hsa-miR-99a may be associated with the pathology of AF. According to the functional annotation analysis, we found that mTOR was one of the most enriched signaling pathways of the host genes of DEcircRNAs. MTOR is a protein kinase that acts as an interface to a variety of metabolic pathways and is widely found in many species. MTOR plays a vital role in cellular metabolism [45]. Kinases are activated by extracellular growth factor signaling, enhancing cytoplasmic translation processes and protein synthesis. The mTOR pathway is involved in the steady-state process of the heart against stress [46]. The mTOR pathway contributes to the proliferation and survival of cardiomyocytes. In aged mice, knocking out and inhibiting mTOR can prolong survival and inhibit cardiac hypertrophy [47]. This indicated that the mTOR signaling pathway plays an important role in the heart against stress and cardiomyocyte survival, which may be associated with the development of AF. In addition, arrhythmogenic right ventricular cardiomyopathy, dilated cardiomyopathy, and hypertrophic cardiomyopathy were three remarkably enriched signaling pathways of DEmRNAs in ceRNA regulatory network. Arrhythmogenic right ventricular cardiomyopathy is a rare inherited cardiomyopathy characterized by fibro-fatty replacement of cardiomyocytes [48, 49]. Sudden cardiac death and ventricular enlargement are the most common clinical manifestations [50]. Arrhythmogenic right ventricular cardiomyopathy mainly involves the left and right ventricle during disease progression. The enlarged left atrial is associated with the incidence of risk for death in dilated cardiomyopathy patients [51-60]. In addition, extensive atrial fibrosis is observed at autopsy in dilated cardiomyopathy patients [61]. AF is an arrhythmia often complicating the course of hypertrophic cardiomyopathy. It is found that patients with hypertrophic cardiomyopathy have a higher risk (20%) for AF [62, 63]. These reports suggested that arrhythmogenic right ventricular cardiomyopathy, dilated cardiomyopathy, and hypertrophic cardiomyopathy may be involved in the process of AF.

5. Conclusion

Our study found two ceRNA (DEcircRNA-DEmiRNA-DEmRNA) regulatory networks including hsa-circRNA-100053-hsa-miR-455-5p-TRPV1 and hsa-circRNA-005843-hsa-miR-188-5p-SPON1 in AF. In addition, several miRNA-mRNA regulatory pairs including hsa-miR-34c-5p-INMT, hsa-miR-1253-DDIT4L, hsa-miR-508-5p-SMOC2, hsa-miR-943-ACTA1, hsa-miR-338-3p-WIPI1, and hsa-miR-199a-3p-RAP1GAP2 and four signaling pathways such as mTOR, arrhythmogenic right ventricular cardiomyopathy, dilated cardiomyopathy, and hypertrophic cardiomyopathy were also identified. The results of the present study may provide a potential novel field into the molecular mechanisms of AF. However, there are limitations to our study. Firstly, a sample size in the qRT-PCR was small. Larger numbers of samples are further needed to validate the expression of ceRNA (DEcircRNA-DEmiRNA-DEmRNA) regulatory networks including hsa-circRNA-100053-hsa-miR-455-5p-TRPV1 and hsa-circRNA-005843-hsa-miR-188-5p-SPON1 and the most upregulated or downregulated mRNAs/miRNAs/circRNAs in AF. Secondly, he potential deeper mechanism of AF is not investigated. In vivo animal model or in vitro cell experiment is further needed to study the potential biological function of identified circRNAs, miRNAs, and mRNAs.
  62 in total

1.  MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice.

Authors:  Denghong Zhang; Riccardo Contu; Michael V G Latronico; Jianlin Zhang; Jian Ling Zhang; Roberto Rizzi; Daniele Catalucci; Shigeki Miyamoto; Katherine Huang; Marcello Ceci; Yusu Gu; Nancy D Dalton; Kirk L Peterson; Kun-Liang Guan; Joan Heller Brown; Ju Chen; Nahum Sonenberg; Gianluigi Condorelli
Journal:  J Clin Invest       Date:  2010-07-19       Impact factor: 14.808

Review 2.  TRPV1 and TRPV4 channels: potential therapeutic targets for ischemic conditioning-induced cardioprotection.

Authors:  Puneet Kaur Randhawa; Amteshwar Singh Jaggi
Journal:  Eur J Pharmacol       Date:  2014-11-20       Impact factor: 4.432

Review 3.  Arrhythmogenic Cardiomyopathy.

Authors:  Domenico Corrado; Cristina Basso; Daniel P Judge
Journal:  Circ Res       Date:  2017-09-15       Impact factor: 17.367

4.  WIPI1 is a conserved mediator of right ventricular failure.

Authors:  Christos Tzimas; Christoph D Rau; Petra E Buergisser; Gaston Jean-Louis; Katherine Lee; Jeffrey Chukwuneke; Wen Dun; Yibin Wang; Emily J Tsai
Journal:  JCI Insight       Date:  2019-04-25

5.  Prognostic value of left atrial enlargement in patients with idiopathic dilated cardiomyopathy and ischemic cardiomyopathy.

Authors:  Frank Lloyd Dini; Lauro Cortigiani; Umberto Baldini; Andrea Boni; Rossella Nuti; Luca Barsotti; Giovanni Micheli
Journal:  Am J Cardiol       Date:  2002-03-01       Impact factor: 2.778

6.  Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support.

Authors:  Scot J Matkovich; Derek J Van Booven; Keith A Youker; Guillermo Torre-Amione; Abhinav Diwan; William H Eschenbacher; Lisa E Dorn; Mark A Watson; Kenneth B Margulies; Gerald W Dorn
Journal:  Circulation       Date:  2009-02-23       Impact factor: 29.690

Review 7.  mTOR Signaling in Growth, Metabolism, and Disease.

Authors:  Robert A Saxton; David M Sabatini
Journal:  Cell       Date:  2017-03-09       Impact factor: 41.582

8.  Differential Expression of CircRNAs in Embryonic Heart Tissue Associated with Ventricular Septal Defect.

Authors:  Heng Liu; Yin Hu; Bin Zhuang; Jing Yin; Xiao-Hui Chen; Juan Wang; Meng-Meng Li; Jing Xu; Xing-Yun Wang; Zhang-Bin Yu; Shu-Ping Han
Journal:  Int J Med Sci       Date:  2018-05-14       Impact factor: 3.738

9.  Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population.

Authors:  Konstantinos C Siontis; Jeffrey B Geske; Kevin Ong; Rick A Nishimura; Steve R Ommen; Bernard J Gersh
Journal:  J Am Heart Assoc       Date:  2014-06-25       Impact factor: 5.501

10.  Whole-Genome Cardiac DNA Methylation Fingerprint and Gene Expression Analysis Provide New Insights in the Pathogenesis of Chronic Chagas Disease Cardiomyopathy.

Authors:  Laurie Laugier; Amanda Farage Frade; Frederico Moraes Ferreira; Monique Andrade Baron; Priscila Camillo Teixeira; Sandrine Cabantous; Ludmila Rodrigues Pinto Ferreira; Laurence Louis; Vagner Oliveira Carvalho Rigaud; Fabio Antônio Gaiotto; Fernando Bacal; Pablo Pomerantzeff; Edimar Bocchi; Jorge Kalil; Ronaldo Honorato Barros Santos; Edecio Cunha-Neto; Christophe Chevillard
Journal:  Clin Infect Dis       Date:  2017-10-01       Impact factor: 9.079

View more
  11 in total

1.  MicroRNA-34c-5p provokes isoprenaline-induced cardiac hypertrophy by modulating autophagy via targeting ATG4B.

Authors:  Yuhong Zhang; Yanqing Ding; Min Li; Jing Yuan; Youhui Yu; Xueying Bi; Huiqi Hong; Jiantao Ye; Peiqing Liu
Journal:  Acta Pharm Sin B       Date:  2021-09-25       Impact factor: 14.903

Review 2.  The Function and Therapeutic Potential of Circular RNA in Cardiovascular Diseases.

Authors:  Kai Wang; Xiang-Qian Gao; Tao Wang; Lu-Yu Zhou
Journal:  Cardiovasc Drugs Ther       Date:  2021-07-16       Impact factor: 3.727

3.  Hsa_circ_0091581 promotes glioma progression by regulating RMI1 via sponging miR-1243-5p.

Authors:  Jin Qian; Yingna Xu; Xing Xu; Zhenyu Tao; Yang Luo; Yichang Xu; Yong Zhang; Chunfa Qian
Journal:  J Cancer       Date:  2021-04-02       Impact factor: 4.207

Review 4.  Circular RNAs and Cardiovascular Regeneration.

Authors:  Ling Tang; Pengsheng Li; Michelle Jang; Wuqiang Zhu
Journal:  Front Cardiovasc Med       Date:  2021-04-13

Review 5.  Exosomes and Exosomal Non-coding RNAs Are Novel Promises for the Mechanism-Based Diagnosis and Treatments of Atrial Fibrillation.

Authors:  Chaofeng Chen; Qingxing Chen; Kuan Cheng; Tian Zou; Yang Pang; Yunlong Ling; Ye Xu; Wenqing Zhu
Journal:  Front Cardiovasc Med       Date:  2021-12-01

Review 6.  Epigenetic Mechanism and Therapeutic Implications of Atrial Fibrillation.

Authors:  Dan Li; Jiali Nie; Yu Han; Li Ni
Journal:  Front Cardiovasc Med       Date:  2022-01-21

7.  Relationship between Serum miR-106 and MYL4 Levels and the Prevalence, Risk Stratification, and Prognosis of Atrial Fibrillation.

Authors:  Yanfeng Liu; Haiwen Zhou; Yu Tao; Zhicheng Xu; Hengli Lai
Journal:  J Immunol Res       Date:  2022-07-14       Impact factor: 4.493

Review 8.  An Overview of the Advances in Research on the Molecular Function and Specific Role of Circular RNA in Cardiovascular Diseases.

Authors:  Lianli Yin; Yinghua Tang; Yulin Yuan
Journal:  Biomed Res Int       Date:  2022-08-18       Impact factor: 3.246

9.  Complement C3 Aggravates Post-epileptic Neuronal Injury Via Activation of TRPV1.

Authors:  Guang-Tong Jiang; Lin Shao; Shuo Kong; Meng-Liu Zeng; Jing-Jing Cheng; Tao-Xiang Chen; Song Han; Jun Yin; Wan-Hong Liu; Xiao-Hua He; Yu-Min Liu; Lanzi Gongga; Bi-Wen Peng
Journal:  Neurosci Bull       Date:  2021-07-26       Impact factor: 5.271

Review 10.  Emerging Role of Mitophagy in the Heart: Therapeutic Potentials to Modulate Mitophagy in Cardiac Diseases.

Authors:  Yi Luan; Ying Luan; Qi Feng; Xing Chen; Kai-Di Ren; Yang Yang
Journal:  Oxid Med Cell Longev       Date:  2021-09-23       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.